Expression of Tumor Markers in Circulating Tumor Cells of Metastatic Hormone-sensitive Prostate Cancer

Development of a Prognostic Model for Metastatic Hormone-sensitive Prostate Cancer by Sequentially Analyzing the Expression of Tumor Markers in Circulating Tumor Cells

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02723526

Enrollment

100

Registered

2016-03-30

Start date

2016-03-31

Completion date

2019-03-31

Last updated

2016-03-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate Cancer

Keywords

Metastatic Hormone-Sensitive Prostate Cancer；circulating tumor cells；Prognosis；Liquid biopsy

Brief summary

As prostate cancer progresses, tumor cells dissociate and enter the bloodstream. Considered a liquid biopsy, these circulating tumor cells (CTC) can show how a patient's cancer evolves and responds to treatments. The purpose of this study is to determine whether sequentially analyzing the expression of tumor markers in circulating tumor cells in newly diagnosed metastatic hormone-sensitive prostate cancer patients can predict the outcome of these patients.

Interventions

OTHERBlood drawing

Study design

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

MALE

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

1. Male patients; 2. 18 yrs and older, and 80 yrs and younger; 3. Histologically or cytologically proven prostate adenocarcinoma; 4. Imaging examinations including Emission Computed Tomography (ECT),Positron Emission Tomography (PET),Computed Tomography(CT)and Magnetic Resonance Imaging (MRI) revealed non-regional lymph node metastasis, bone metastasis, or visceral metastasis; 5. Not yet receiving hormonal therapy; 6. Not yet receiving chemotherapy previously; 7. Not yet receiving radical prostatectomy, radiotherapy, or transurethral resection of the prostate (TURP) previously; 8. Patients are willing to participate and can be followed up regularly；

Exclusion criteria

1. Received radical prostatectomy, radiotherapy, or transurethral resection of the prostate (TURP) previously; 2. Received androgen deprivation therapy (including surgical castration, medical castration, anti-androgen therapy, and maximum androgen blockade) before inclusion; 3. Patients received chemotherapy previously; 4. Combined with other malignant tumor history (in addition to the skin basal cell carcinoma or other tumors that have been cured more than five years);

Design outcomes

Primary

Measure	Time frame
time to castration-resistant prostate cancer	3 years

Secondary

Measure	Time frame
time to radiographic progression	3 years
time to prostate specific antigen (PSA) progression	3 years
time to prostate specific antigen (PSA) nadir	2 years
complete serologic response rate at 6 month and 12 month	1 years

Countries

China

Contacts

Primary ContactBo Dai, MD

bodai1978@126.com+86-21 64175590

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026